GAD-65 Antibodies

Santa Cruz Biotechnology delivers a wide array of GAD-65 monoclonal antibodies for research focused on understanding Glutamic Acid Decarboxylase 65 (GAD-65) in various biological processes. GAD-65 Antibodies are validated for multiple applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). GAD-65 is a key enzyme involved in the synthesis of gamma-aminobutyric acid (GABA), a critical neurotransmitter that plays a significant role in regulating neuronal excitability throughout the nervous system. Dysregulation of GAD-65 has been implicated in various neurological disorders, including epilepsy and autoimmune conditions such as type 1 diabetes. Understanding the function and regulation of GAD-65 is essential for developing therapeutic strategies targeting these conditions. GAD-65 monoclonal antibodies enable precise detection and analysis of protein expression patterns in neural tissues. Researchers can effectively track GAD-65 localization and expression levels across different experimental conditions. Advanced research techniques utilizing GAD-65 monoclonal antibodies help reveal new insights about neural signaling pathways and disease mechanisms. Santa Cruz Biotechnology monoclonal antibodies for GAD-65 support researchers worldwide in advancing our understanding of neurological disorders and potential therapeutic approaches.